ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk.

Hans-Peter Hartung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.